Symbol Name Last Trade Price Change Change (%) Volume

Revenue 1 year Target Price 52 week Range Stock Exchange Last Trade Size

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Company is engaged in developing product candidates that focus on the body’s peripheral nervous system. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845, and CR701. The Company’s I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. The Company is developing an oral version of CR845 for the treatment of moderate-to-severe acute and chronic pain. The Company’s CR701 is a peripherally-restricted, mixed-CB1/CB2 receptor agonist that interacts with cannabinoid receptor subtypes, with no off-target activities. CR701 is in preclinical-stage of development.

Breaking News Arrows

Breaking News

  • New Cannabis Products Which Could Disrupt the Industry in 2020January 15, 2020The cannabis industry enjoyed tremendous investor enthusiasm in 2018, fueled in large part by major developments which seemed to open up the space for new opportunities. In spite of the fact that cannabis stocks overall failed to perform up to expectations last year, 2019 has already revealed continued anticipation regarding this growing industry. If cannabis stocks are to thrive going forward, it's likely that many companies will have some growing up to do.
  • Cara Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2020STAMFORD, Conn., Jan. 08, 2020 — Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a.
  • Was Smart Money Right About Piling Into Cara Therapeutics Inc (CARA) in September?December 20, 2019Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]
  • Cara Therapeutics Announces Equity Grants to Employees Under Inducement PlanDecember 6, 2019Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Compensation Committee of Cara’s Board of Directors has approved the grant of non-qualified stock options to purchase an aggregate of 47,500 shares of common stock, to be distributed among two new non-executive employees, pursuant to Cara’s 2019 Inducement Plan. The awards have a grant date of December 2, 2019 and an exercise price of $25.88 per share, which is equal to the closing price of Cara’s common stock on the date of grant. The stock options were granted as inducement material to each new employee entering into employment with Cara in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Edited Transcript of CARA earnings conference call or presentation 5-Nov-19 9:30pm GMTDecember 6, 2019Q3 2019 Cara Therapeutics Inc Earnings Call